Golimumab - Biologic Drug Details

Summary for golimumab

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for golimumab

Recent Clinical Trials for golimumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Universitaire Ziekenhuizen KU Leuven	PHASE4
NYU Langone Health	PHASE2
IRCCS Ospedale San Raffaele	NA

See all golimumab clinical trials

Pharmacology for golimumab

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for golimumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for golimumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2034-03-18	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2038-01-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2038-03-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2032-03-05	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2036-09-14	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2040-08-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for golimumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2035-06-16	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2033-12-23	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2036-12-20	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2037-03-16	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2032-04-20	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289		2036-08-10	Patent claims search

International Patents for golimumab

Country	Patent Number	Estimated Expiration
South Korea	20180108480
Israel	268160
Denmark	2558499
Poland	3140319
Croatia	P20191671
China	113633906

Supplementary Protection Certificates for golimumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB04/002	United Kingdom		PRODUCT NAME: ADALIMUMAB; REGISTERED: CH 56'221 20030416; UK EU/1/03/257/001 20030901; UK EU/1/03/257/002 20030901; UK EU/1/03/257/003 20030901; UK EU/1/03/257/004 20030901; UK EU/1/03/257/005 20030901; UK EU/1/03/257/006 20030901
239	Finland
CA 2004 00002	Denmark		PRODUCT NAME: ADALIMUMAB
2/2004	Austria		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001- EU/1/03/257/006 20030901; FIRST REGISTRATION: LI 56221 20030416
04C0001	France		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: LI - 56221 20030416
2004C/002	Belgium		PRODUCT NAME: ADALIMUMAB; AUTHORISATION NUMBER AND DATE: 56221 20030902

Golimumab (Biologic): Market Dynamics and Financial Trajectory

Last updated: April 28, 2026

What is golimumab’s market footprint by indication and geography?

Golimumab (a TNF-alpha inhibitor; brand: Simponi and Simponi Aria) is a chronic, long-term therapy whose market performance tracks three drivers: (1) persistent demand in biologic-naive and switching patients, (2) biosimilar erosion by molecule and formulation, and (3) payer behavior around step therapy and site-of-care.

Across major markets, golimumab is used in inflammatory disease settings:

• Rheumatoid arthritis (RA) (Simponi; and IV Simponi Aria in the US)
• Psoriatic arthritis (PsA) (Simponi)
• Ankylosing spondylitis (AS) (Simponi)

Global commercialization pattern: golimumab has historically sold best where TNF inhibitors are standard of care and where dosing convenience (monthly subcutaneous dosing; IV option in some geographies) supports retention. After biosimilar entry, performance tends to compress through contract re-pricing, formulary placement shifts, and conversion to lower-cost alternatives.

Implication for financial trajectory: once biosimilars win formulary share, revenue growth stops and declines accelerate unless the originator can offset with patient retention programs, contract duration, or new-line uptake through clinical differentiation.

---

How have biosimilars reshaped pricing, volume, and revenue?

Golimumab faces biosimilar competition. The commercial impact typically shows up in three phases:

1. Launch phase (first 6 to 18 months): payers test lower-cost options; share shift starts unevenly by channel (hospital vs retail infusion vs specialty pharmacy).
2. Contract renewal phase (12 to 36 months): deeper discounts and broader formulary placement compress net price; switching rises.
3. Stabilization or acceleration (36+ months): net price erosion continues while volume is partially protected by existing patients and dosing persistence, then new-patient starts increasingly favor biosimilars.

Mechanisms that drive erosion for golimumab specifically:

• TNF class crowding: multiple TNF biologics compete; payer incentives increase when several options are “equivalent” in their eyes.
• Formulary and rebate mechanics: originator net price declines faster than list price once multiple biosimilars anchor the low end.
• Channel differences: IV products can face faster hospital contracting changes; subcutaneous uptake can be slower due to patient retention.

---

What does the financial trajectory look like after competitive entry?

Golimumab’s revenue path is characterized by:

• High baseline revenue prior to biosimilar pressure
• Post-entry revenue decline driven by net price compression and reduced share
• Ongoing offset to the downside from durability of care (chronic use, switching latency, and physician familiarity)

Core accounting lens: because biosimilar pressure primarily hits net price and utilization mix, revenue declines can begin before gross-to-net worsens sharply, then accelerate when contracts renew.

Investment-grade read-through:

• If biosimilar penetration rises faster than anticipated, revenue declines steepen.
• If contracts lock in originator pricing temporarily, revenue may remain flatter in the short term, then drop at renewal.

---

What market dynamics move golimumab’s unit economics?

1) Net price and rebate intensity

Golimumab’s economics depend on gross-to-net, which is shaped by:

• payer rebates and access arrangements
• hospital purchasing contracts
• pharmacy benefit manager behavior in specialty carve-outs

2) Treatment line mix

Golimumab competes not only by molecule but also by:

• prior biologic exposure (switching vs biologic-naive patterns)
• comorbidities and clinician preference within TNF class
• adherence to chronic therapy (persistence affects revenue more than early uptake)

3) Safety and persistence profile

TNF inhibitors share a safety framework; switching decisions often center on:

• prior response and tolerability
• route of administration preference
• dosing schedule fit

Those factors can delay attrition for existing patients even when new patient starts shift to biosimilars.

---

How do channel and route-of-administration affect performance?

Golimumab’s routes:

• Subcutaneous (Simponi)
• Intravenous (Simponi Aria)

Channel effects:

• IV / hospital-based channels usually experience faster formulary and contract shifts because procurement is more centralized.
• Subcutaneous / self-administered channels retain more inertia because switching involves patient training, insurance authorization, and pharmacy benefits.

Financial outcome: revenue erosion is typically visible first in IV/hospital-heavy channels where contracting can re-price quickly; subcutaneous demand often shows slower, more persistent declines.

---

What are the dominant competitive vectors in RA, PsA, and AS?

Rheumatoid arthritis

RA has:

• higher competition density across TNF and non-TNF mechanisms
• strong payer emphasis on step therapy after inadequate response

Golimumab performs best in stable prescriber patterns and where biosimilars gain share gradually. Once biosimilars become the default at major payers, the originator’s net price compresses materially.

Psoriatic arthritis

PsA demand is driven by:

• treatment guideline adherence
• switching behavior among biologic-naive and TNF-experienced patients

Biosimilar penetration tends to translate into faster uptake because PsA often has a broad pool of alternative biologics.

Ankylosing spondylitis

AS has strong TNF-class adoption and persistent chronic treatment patterns. That can slow the decline, but TNF biosimilar contracting tends to override persistence once switching is incentivized.

---

What is the likely shape of the revenue curve (base case pattern)?

A practical revenue curve for an originator TNF biologic after biosimilar entry typically follows:

• Plateau at launch: share loss is partially offset by residual demand and existing patients
• Downshift during renewal windows: abrupt steps as contracts reset pricing and PBM incentives
• Long tail with continued erosion: declines persist but at a slower rate if originator retains some protected share

For golimumab, that translates into a steady erosion profile rather than a one-time collapse, unless:

• multiple biosimilar entrants compete aggressively at once, or
• large payers accelerate automatic substitution and narrow preferred formularies.

---

What does the competitive landscape imply for future financial trajectory?

Golimumab’s medium-term trajectory is dominated by:

• biosimilar market share
• payer contract duration
• route/channel mix
• competitive position versus other TNF inhibitors and non-TNF classes

If biosimilars become the preferred default across major payers, financial performance continues to compress through:

• declining new-patient starts
• higher switching rates among stable patients when renewal incentives are available
• persistent gross-to-net pressure

If payer access is fragmented and originator contracts remain protected longer, revenue declines can extend as a slower downtrend, but the direction remains negative once biosimilar share becomes entrenched.

---

What are the key business implications for R&D and portfolio strategy?

1. Access strategy beats clinical differentiation post-entry. For an older TNF molecule, differentiation is not enough if payer economics drive switching.
2. Channel-specific tactics matter. IV/hospital performance typically erodes earlier under centralized procurement; subcutaneous can retain share longer.
3. Contract timing creates step changes. Modeling revenue should incorporate renewal windows and formulary refresh cycles.
4. Portfolio risk is path-dependent. The molecule’s value depends on how quickly payer networks adopt biosimilar default placement and how long originator contracts delay re-pricing.

---

Key Takeaways

• Golimumab’s market dynamics are dominated by biosimilar-driven net price erosion, with revenue declines shaped by payer contract renewals and channel differences.
• The financial trajectory is typically plateau then stepped decline, followed by a long-tail erosion supported only by persistence of existing patients.
• Route-of-administration matters: IV channels tend to re-price faster than subcutaneous channels.
• For forward-looking planning, the critical variables are biosimilar share gain speed, gross-to-net compression, and formulary placement velocity by major payers.

---

FAQs

1. Why does golimumab revenue usually decline in steps after biosimilar entry?
   Pricing resets and formulary updates occur at contract and renewal cycles, producing stepwise erosion rather than a smooth linear decline.

2. Which channel is usually hit first for golimumab-like biologics?
   Hospital/IV procurement often re-contracts faster than specialty pharmacy subcutaneous channels.

3. Does patient persistence slow biosimilar impact?
   Yes. Existing patients can persist despite biosimilar availability, but switching increases after payer incentives tighten.

4. How do RA, PsA, and AS differ in competitive pressure?
   PsA and RA often face broader therapeutic alternative density and step-therapy pressure; AS can retain TNF-class users longer, but TNF biosimilar contracting still drives erosion.

5. What’s the most important metric for golimumab’s financial trajectory?
   Net price (gross-to-net) and utilization mix, driven by formulary status and payer contracting.

---

References

[1] US Food and Drug Administration. (n.d.). Simponi and Simponi Aria (golimumab) prescribing information. FDA.
[2] EMA. (n.d.). Simponi (golimumab) product information. European Medicines Agency.
[3] IQVIA Institute / industry publications. (n.d.). Biologics and biosimilars market dynamics and biosimilar adoption trends. IQVIA.
[4] Public company filings (Johnson & Johnson). (n.d.). Notes on Simponi and biosimilar competition disclosures. Annual reports and earnings presentations.